VTX-PID is a technology aimed to deplete Neutralizing Antibodies (NAbs) levels for a given AAV serotype, to a level allowing proper AAV transduction and therefore desired efficacy. VTX-PID is developed both for patients presenting NAbs because of a previous infection and therefore non eligible for gene therapy; and for patients in need of gene therapy re-administration in case of loss of efficacy.
VTX-806 is an AAV-based gene therapy for Cerebrotendinous xanthomatosis (CTX). It delivers a codon-optimized version of the CYP27A1 gene to the liver with strong proof-of-concept data in animals. VTX-806 has received Orphan Drug designations from both the FDA and the European Commission (EC) and proposed IND Regulatory strategy is supported by the FDA.
VTX-801, Vivet’s investigational gene therapy for Wilson’s Disease (WD), has received Orphan Drug and Fast Track designations from both the FDA and the EC.
The WD Gateway trial has stopped recruitment and is now focused exclusively on long-term follow-up of the already treated patients, with five years of monitoring planned.
Data from this trial will be published as further results become available.
Vivet Therapeutics has investors from both sides of the ocean, bringing strong support, network and long-term commitment.
By developing a unique pipeline of liver-directed AAV products and pioneering new technologies, we strive to unlock life-changing treatments for those in need. Recognizing that neutralizing antibodies prevent 20–50% of people from accessing gene therapy, we are committed to creating innovative solutions giving chance to more patients for effective therapies and even possible cures. Our mission is to expand access and make a difference in the lives of patients who previously had limited or no treatment options.
We are constantly looking for new ideas. Today, we live in an era of extraordinary progress and innovation where we can drive science to create extraordinary opportunities for patients and their families.
By developing a unique pipeline of liver-directed AAV products and pioneering new technologies, we strive to unlock life-changing treatments for those in need. Recognizing that neutralizing antibodies prevent 20–50% of people from accessing gene therapy, we are committed to creating innovative solutions giving chance to more patients for effective therapies and even possible cures. Our mission is to expand access and make a difference in the lives of patients who previously had limited or no treatment options.
We are constantly looking for new ideas. Today, we live in an era of extraordinary progress and innovation where we can drive science to create extraordinary opportunities for patients and their families.
Sevilla, October 2025 – At the 32nd Annual Congress of the European Society of Gene & Cell Therapy (ESGCT), Vivet Therapeutics shared new clinical data
Join us at ESGCT 2025 in Sevilla for an important presentation by Jean-Philippe Combal from Vivet Therapeutics on October 9th at 10:00am CET during the session entitled
We are excited to share our paper on Pilot clinical study showing abnormal copper metabolism in healthy Wilson disease heterozygote subjects, accepted to CTSJournal. See
Vivet Therapeutics is pleased to announce that our CEO, Jean-Philippe Combal, will be attending the Jefferies Global Healthcare Conference in London from November 18th to
Join our CEO, @Jean-Philippe Combal in the Big Apple for @Chardan’s 9th Annual Genetic Medicines Conference! The premier event will bring together groundbreaking thought leaders
Vivet Therapeutics is excited to announce two poster presentations at ESGCT 2025 in Sevilla, showcasing innovative advances in liver-directed gene therapy. Catch us on Thursday,
